WellCare of Kentucky does not cover Wegovy for weight loss under its Medicaid plan. Kentucky Medicaid excludes drugs prescribed primarily for weight loss, and a 2026 state law locks that exclusion in place. Wegovy is available through Kentucky Medicaid only for two narrow non-weight indications, and only with prior authorization. If you’re on a WellCare Medicare plan instead, there’s a separate federal program starting July 1, 2026 that can put Wegovy within reach at $50 a month for weight reduction.
Why Kentucky Medicaid Won’t Pay for Wegovy for Weight Loss
Kentucky Medicaid has long excluded medications used for weight loss, relying on a federal provision that lets state Medicaid programs leave those drugs off their formularies even when the FDA has approved them for that use.1KFF. Medicaid Coverage of and Spending on GLP-1s The state’s GLP-1 receptor agonist prior authorization criteria, updated in October 2025, require prescribers to confirm that semaglutide and similar drugs are being used for Type 2 diabetes and to attest they are not being used for weight-related purposes.2Kentucky Medicaid Portal (MedImpact). GLP-1 Receptor Agonists Prior Authorization Criteria Changes
Wegovy itself does not appear on the Kentucky Medicaid Preferred Drug List as of June 2026.3Kentucky Medicaid Portal (MedImpact). Kentucky Medicaid PDL
The 2026 Kentucky legislature reinforced this policy through House Bill 2, which prohibits Medicaid coverage of prescription drugs prescribed primarily for weight loss, and Senate Bill 65, which nullified a proposed administrative regulation that would have removed the ban. Governor Andy Beshear vetoed both measures, and the legislature overrode both vetoes in April 2026.4Hoptown Chronicle. Final Round Up: Health Related Bills Passed During 2026 Legislative Session The regulatory path that would have opened Medicaid coverage for weight-loss GLP-1s has been closed.
The Two Ways Wegovy Can Be Approved Under Kentucky Medicaid
Wegovy is available through Kentucky Medicaid for two specific medical indications under prior authorization criteria effective January 3, 2026. Both pathways exclude patients with Type 2 diabetes.5Kentucky Medicaid Portal (MedImpact). Wegovy PA Criteria Effective 1.3.2026
Cardiovascular Risk Reduction
Wegovy may be approved for patients 45 or older with established cardiovascular disease, such as a prior heart attack, stroke, or symptomatic peripheral artery disease. The patient must have a BMI of at least 27, be on optimized heart medications including a statin, and be following a diet and exercise plan. A hemoglobin A1c of 6.5% or higher, Class IV heart failure, or end-stage kidney disease disqualifies the patient.5Kentucky Medicaid Portal (MedImpact). Wegovy PA Criteria Effective 1.3.2026
Liver Disease (MASH)
Wegovy injections may also be approved for adults 18 and older with metabolic dysfunction-associated steatohepatitis and moderate to advanced fibrosis. The diagnosis must be confirmed by liver biopsy or by specific blood and imaging tests, and the prescription must come from or be coordinated with a gastroenterologist or hepatologist. Cirrhosis and liver cancer are exclusions, and the tablet form is not approved for this use.5Kentucky Medicaid Portal (MedImpact). Wegovy PA Criteria Effective 1.3.2026
For either indication, approvals last six months and require renewal with documentation of benefit, such as at least a 5% reduction in body weight for cardiovascular patients or improved fibrosis scores for MASH patients. Only one GLP-1 formulation is allowed at a time, and Wegovy cannot be combined with another GLP-1 or dual GLP-1/GIP receptor agonist.6Kentucky Medicaid Portal (MedImpact). Kentucky Wegovy Prior Authorization Policy
If You’re on WellCare Medicare in Kentucky
Standard Medicare Part D does not cover drugs prescribed solely for weight loss. Under WellCare’s Part D and Medicare Advantage plans, Wegovy may be covered only when it’s prescribed to reduce cardiovascular risk in adults with established heart disease who are overweight or obese, and only if the drug appears on your specific plan’s formulary. Prior authorization, step therapy, or quantity limits may apply.7WellCare. Does Medicare Cover Weight Loss Drugs
The Medicare GLP-1 Bridge Program
Starting July 1, 2026, a federal demonstration called the Medicare GLP-1 Bridge offers a separate route to Wegovy for weight reduction. The Bridge operates outside the regular Part D benefit. It isn’t run by WellCare or any Part D plan; a single central processor handles all prior authorization requests and claims. Eligible Medicare beneficiaries pay a flat $50 copay per monthly supply, regardless of which Part D plan they’re enrolled in.8CMS. Medicare GLP-1 Bridge
Eligibility depends on your BMI and other health conditions:
- BMI of 35 or higher qualifies on its own.
- BMI between 30 and 34.99 qualifies with a condition such as uncontrolled hypertension, chronic kidney disease (stage 3a or higher), prediabetes, or a history of heart attack or stroke.
- BMI between 27 and 29.99 qualifies only with prediabetes, a history of heart attack or stroke, or symptomatic peripheral artery disease.
You are not eligible if you already receive GLP-1 drugs through your Part D plan or if you have Type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease.9Medicare.gov. Weight Loss Drugs The program is set to run through at least December 2027.10CMS. CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries
What Wegovy Costs Without Coverage
Without insurance coverage, Wegovy runs roughly $1,350 for a one-month supply at list price.11GoodRx. Wegovy for Weight Loss: Cost and Coverage Novo Nordisk offers two ways to bring that down, but neither is open to people on Medicaid, Medicare, or other government-funded coverage.
Patients with commercial insurance may qualify for a savings card that brings their cost as low as $25 per month, with a maximum savings of $100 per month.12NovoCare. Wegovy Savings Offer Patients paying cash through NovoCare Pharmacy can get certain doses starting at $149 per month. New patients may pay $199 per month for the first two months at introductory doses, rising to $349 per month for the injection at standard doses after the introductory period.13Wegovy.com. What to Pay for Wegovy
Before filling a prescription, you can check your coverage through the benefits tool on the NovoCare website.13Wegovy.com. What to Pay for Wegovy